William Seibel

6PUBLICATIONS
59CO-AUTHORS
Cheminformatics and quantitative structure-activity relationshipsNeurology and neuromuscular diseasesClinical pharmacology and therapeuticsMolecular targetsAutoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 30, 2024
Accelerating drug discovery and repurposing by combining transcriptional signature connectivity with docking.

Alexander W Thorman, James Reigle, Somchai Chutipongtanate

|Jul 17, 2024
Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.

Stephanie J Bouley, Andrew V Grassetti, Robert J Allaway

|Feb 25, 2023
Structure-Activity Relationship Analysis of Rhosin, a RhoA GTPase Inhibitor, Reveals a New Class of Antiplatelet Agents.

Akhila Dandamudi, William Seibel, Benjamin Tourdot

|Aug 31, 2022
Rational polypharmacological targeting of FLT3, JAK2, ABL, and ERK1 suppresses the adaptive resistance to FLT3 inhibitors in AML.

Mohammad Azhar, Zachary Kincaid, Meenu Kesarwani

|Mar 09, 2022
Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia.

Laura Barreyro, Avery M Sampson, Chiharu Ishikawa

|Oct 29, 2021
Inhibition of the RacGEF VAV3 by the small molecule IODVA1 impedes RAC signaling and overcomes resistance to tyrosine kinase inhibition in acute lymphoblastic leukemia.

Shailaja Hegde, Anjelika Gasilina, Mark Wunderlich

Pageof 1

Frequent Collaborators

2 joint publications

Somchai Chutipongtanate

2 joint publications

Mark Wunderlich

1 joint publications

Laura Barreyro

1 joint publications

Avery M Sampson